Literature DB >> 20084490

[Rosuvastatin for primary prevention of vascular events : JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin).]

G Klose1, W März, T B Grammer, S Nitschmann.   

Abstract

Entities:  

Year:  2010        PMID： 20084490     DOI： 10.1007/s00108-009-2570-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  8 in total

Review 1.  Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.

Authors:  M R Law; N J Wald; A R Rudnicka
Journal:  BMJ       Date:  2003-06-28

2.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Authors:  P M Ridker; N Rifai; M Clearfield; J R Downs; S E Weis; J S Miles; A M Gotto
Journal:  N Engl J Med       Date:  2001-06-28       Impact factor: 91.245

Review 3.  Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis.

Authors:  Bernd Genser; Winfried März
Journal:  Clin Res Cardiol       Date:  2006-06-20       Impact factor: 5.460

4.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

5.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

6.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Authors:  Robert J Glynn; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Paul M Ridker
Journal:  N Engl J Med       Date:  2009-03-29       Impact factor: 91.245

Review 7.  The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis.

Authors:  Philippa J Delahoy; Dianna J Magliano; Kate Webb; Mendel Grobler; Danny Liew
Journal:  Clin Ther       Date:  2009-02       Impact factor: 3.393

8.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.